TY - JOUR
T1 - Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system
AU - Cani, Alice
AU - Parenzan, Caterina Tretti
AU - Frasson, Chiara
AU - Rampazzo, Elena
AU - Scarparo, Pamela
AU - Francescato, Samuela
AU - Caicci, Federico
AU - Barbieri, Vito
AU - Rosato, Antonio
AU - Cesaro, Simone
AU - Zecca, Marco
AU - Micalizzi, Concetta
AU - Sainati, Laura
AU - Pigazzi, Martina
AU - Biffi, Alessandra
AU - Buldini, Barbara
AU - Locatelli, Franco
AU - Persano, Luca
AU - Masetti, Riccardo
AU - Te Kronnie, Geertruij
AU - Bresolin, Silvia
PY - 2023
Y1 - 2023
N2 - Juvenile myelomonocytic leukemia (JMML) is a rare clonal stem cell disorder that occurs in early childhood and is characterized by the hyperactivation of the RAS pathway in 95% of the patients. JMML is characterized by a hyperproliferation of granulocytes and monocytes, and little is known about the heterogeneous nature of leukemia-initiating cells, as well as of the cellular hierarchy of the JMML bone marrow. In this study, we report the generation and characterization of a novel patient-derived three-dimensional (3D) in vitro JMML model, called patient-derived JMML Atypical Organoid (pd-JAO), sustaining the long-term proliferation of JMML cells with stem cell features and patient-specific hallmarks. JMML cells brewed in a 3D model under different microenvironmental conditions acquired proliferative and survival advantages when placed under low oxygen tension. Transcriptomic and microscopic analyses revealed the activation of specific metabolic energy pathways and the inactivation of processes leading to cell death. Furthermore, we demonstrated the pd-JAO-derived cells' migratory, propagation, and self-renewal capacities. Our study contributes to the development of a robust JMML 3D in vitro model for studying and defining the impact of microenvironmental stimuli on JMML disease and the molecular mechanisms that regulate JMML initiating and propagating cells. Pd-JAO may become a promising model for compound tests focusing on new therapeutic interventions aimed at eradicating JMML progenitors and controlling JMML disease.
AB - Juvenile myelomonocytic leukemia (JMML) is a rare clonal stem cell disorder that occurs in early childhood and is characterized by the hyperactivation of the RAS pathway in 95% of the patients. JMML is characterized by a hyperproliferation of granulocytes and monocytes, and little is known about the heterogeneous nature of leukemia-initiating cells, as well as of the cellular hierarchy of the JMML bone marrow. In this study, we report the generation and characterization of a novel patient-derived three-dimensional (3D) in vitro JMML model, called patient-derived JMML Atypical Organoid (pd-JAO), sustaining the long-term proliferation of JMML cells with stem cell features and patient-specific hallmarks. JMML cells brewed in a 3D model under different microenvironmental conditions acquired proliferative and survival advantages when placed under low oxygen tension. Transcriptomic and microscopic analyses revealed the activation of specific metabolic energy pathways and the inactivation of processes leading to cell death. Furthermore, we demonstrated the pd-JAO-derived cells' migratory, propagation, and self-renewal capacities. Our study contributes to the development of a robust JMML 3D in vitro model for studying and defining the impact of microenvironmental stimuli on JMML disease and the molecular mechanisms that regulate JMML initiating and propagating cells. Pd-JAO may become a promising model for compound tests focusing on new therapeutic interventions aimed at eradicating JMML progenitors and controlling JMML disease.
KW - N/A
KW - N/A
UR - http://hdl.handle.net/10807/244214
U2 - 10.1182/bloodadvances.2021006746
DO - 10.1182/bloodadvances.2021006746
M3 - Article
SN - 2473-9529
VL - 7
SP - 1513
EP - 1524
JO - Blood advances
JF - Blood advances
ER -